Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Ivan Špıčka, Jakub Radocha, Paweł Robak, Kihyun Kım, Michèle Cavo, Kazuhito Suzuki, S. Yousuf Zafar, Ainslee Moore, Michael Duggan, Kristin Morris, Amy Phillips-Jones, Margaret Polinkovsky, Jayleen Grams, Ianire Garrobo-Calleja, Elisabet E. Manasanch, Brandon E. Kremer, Joanna Opalińska, María‐Victoria Mateos, Meletios A Dimopoulos (2025). Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-2264.
